Increased basal plasma FFA and lactate concentrations are often present in obesity and may deeply affect insulin action. The inhibition of glucose transport or phosphorylation is thought to be involved in this phenomenon, but the molecular mechanisms on the basis are still unknown. In our laboratory we observed that a chronic infusion of Intralipid plus heparin in rats signi®cantly decreased the insulin dependent-glucose uptake, as well as GLUT4 gene expression in muscular tissue. On the other hand it has been shown that an enhanced plasma lactate concentration may increase insulin secretion and hepatic insulin clearance. Moreover we observed that chronic hyperlactatemia in rats is able to decrease glucose uptake in muscles, while reducing GLUT4 mRNA and protein in the same tissues. In obesity, lactate and FFA overproduction from visceral fat may therefore play a synergic role in reducing insulin sensitivity. International Journal of Obesity (2000) 24, Suppl 2, S22±S24 Keywords: insulin resistance; substrate competition; lactate; free fatty acids; GLUT4
Obesity can be de®ned as a syndrome characterized by an increase in body fat stores, mainly due to an imbalance between energy intake and energy expenditure.
As a consequence of the enlargement of adipose tissue mass a complex alteration of fuel storage and mobilization may occur at adipose tissue level. In particular, several metabolites (ie FFA, lactate, etc.) and local modulators (ie adenosine, prostaglandins, cytokines, leptin, etc) should be considered as potential factors acting on insulin secretion and on glucose and lipid metabolism. It is also well known that profound changes in hormone secretion and metabolism (sex steroids, growth hormone, etc) occur in obesity and it may well be that these changes may in¯uence insulin secretion and action. 1 The main purpose of this review is to focus attention on the role that an increased availability of fuels mobilized from adipose tissue may play in the progression from obesity to diabetes.
It is well known that obese patients display increased rates of lipid oxidation and enhanced concentrations of free fatty acids (FFA) in their blood. Tracer studies demonstrate that they have increased rates of glycerol and FFA turnover, indicating increased lipolysis. 2 At the skeletal muscle and adipose cell level, where insulin stimulates glucose oxidation, increased oxidation rates of other macro nutrients, driven by their increased blood concentration, may interfere with glucose oxidation and hence its utilization. The existence of a glucose ± FFA competition is a well-known metabolic process. The concept that elevated blood levels of FFA play a key role in the development of insulin resistance in obesity and type 2 diabetes was ®rst proposed by Randle et al, 3 more than 30 years ago. The consequences of an increased FFA availability and utilization on glucose metabolism has been found to be time dependent. In fact it was shown that lipid infusion within 3 ± 4 h inhibited glucose oxidation without changing glucose uptake. The glucose carbons that could not be oxidized where shunted into lactate and alanine production. After the initial 3 ± 4 h, FFA were shown to selectively inhibit insulin-stimulated glucose uptake, while they did not affect the glucose uptake stimulated by hyperglycemia or the one in basal conditions. 4 The inhibition of glucose transport or phosphorylation is thought to be involved in this phenomenon, but the cellular and molecular mechanisms responsible for these defects are not clear. Possibilities include the fatty acid-induced inhibition of insulin-stimulated glucose transport via the accumulation of glucosamine pathway metabolites. 5 However a direct effect of FFA on glucose transporter is still under debate. In experiments carried out in freely-moving rats we observed that a chronic infusion of Intralipid plus heparin was able to signi®cantly decrease the insulin-dependent glucose uptake at the level of skeletal muscle and heart. Moreover, both GLUT4 mRNA and protein signi®cantly decreased in the same muscle groups. Hence, there is currently strong evidence that physiological elevations of plasma FFA levels lower peri pheral insulin sensitivity dose dependently. It is reasonable to assume that chronically elevated plasma levels of FFA, perhaps together with FFA released from intramuscular fat depots, 6 are contributing to the insulin resistance commonly seen in obesity.
However, competition between substrates is a more complex phenomenon, involving fuels other than FFA and glucose and diversion to cells where they can be preferentially taken up and utilized. For instance, a glucose sparing effect by non-glucidic fuels has been demonstrated for ketone bodies. Inhibition of glucose uptake and oxidation in muscles and heart by increased ketone bodies has been explained by the observation that these substrates inhibit glucose oxidation acting at the level of pyruvate dehydrogenase. 7 A fuel interaction has also been suggested for lactate and FFAs, since lactate infusion resulted in a clear reduction in the release of FFAs from fat stores and their oxidation in dogs. 8 Recently evidence has accumulated indicating that adipose tissue is able to convert glucose into lactate. This process, far from being a negligible metabolic pathway, has been found to signi®cantly contribute to the whole lactate pool. This hypothesis is further supported by the ®nding that in humans peripheral lactate concentration is correlated with body fat mass, 9 thus suggesting a link between lactate plasma levels and the size of the adipose organ. Moreover, the increment in blood lactate after oral and intravenous glucose load is negatively correlated with BMI. 10 Type 2 diabetes is also characterized by increased lactate rate of appearance in basal conditions, 11 while during oral glucose load and during euglycemic hyperinsulinemic clamp there is a blunted lactate formation. 12 These observations suggest the hypothesis that alterations in lactate metabolism may be linked to insulin resistance. A few years ago Di Girolamo put forward the hypothesis that, in conditions in which insulin resistance and increased lactate concentration are present, namely obesity and diabetes, the latter is not only a consequence of the former, but might possibly play a pathogenetic role in the perpetuation of insulin resistance. 13 Therefore, we investigated the effect of sustained lactate infusion on overall glucose metabolism as a quantitative in vivo measurement of insulin sensitivity in individual tissues in rats.
14 In our experience, peripheral glucose disposal as assessed by clamp technique was signi®cantly reduced by lactate infusion, suggesting that an enhanced availability of this end product of glucose metabolism may affect insulindependent glucose uptake and utilization.
In order to determine the relative contribution of the different tissues to the lowering effect of lactate on whole body glucose utilization, we measured the glucose utilization index in skeletal muscles using the 2-deoxy-(1-3 H)-glucose technique. We observed a marked reduction of glucose utilization by red muscles and heart, but not white adipose tissue. Speci®c lactate transporters have been reported in both skeletal and heart muscle 15 and hyperinsulinemia was found to increase lactate utilization. 16 Therefore, it is possible to speculate that, in a condition characterized by a great availability of lactate, this fuel could be utilized preferentially or to the detriment of an adequate glucose utilization, con®rming previous in vitro experiments in which isolated rat soleus was used. 17 The lactate-induced reduction in muscular glucose utilization was con®rmed in further experiments, in which lean rats were chronically infused with lactate. In the same animals a reduced GLUT4 gene expression in skeletal muscles was observed, suggesting that lactate may directly interfere with insulin-dependent glucose transport. 18 As reported for FFA, lactate was also shown to participate in the control of insulin secretion. A few years ago, we observed that, in dogs, lactate infusion in the pancreatic artery induced an increase of insulin secretion, thus supporting the idea of a direct in¯u-ence of lactate on b-cell function. 19 Likewise, lactate plays a role in regulating hepatic insulin clearance, as we demonstrated using a model of non recirculating perfused rat liver. 20 In our experiments rat liver was perfused in situ with saline or increasing concentrations of sodium lactate; hepatic insulin extraction was then calculated from the difference in insulin concentration between the portal and the suprahepatic vein. Our results showed that hepatic insulin extraction at the three lactate concentrations added was higher than in the control experiments. Thus, energy fuels such as lactate and FFA have opposite effects on hepatic insulin clearance and may therefore contribute to the regulation of posthepatic insulin delivery.
In summary, our results strongly suggest that, in obesity, an increased availability of fuels, such as FFA and lactate, may derive from an enlarged adipose mass. Their increase in blood may deeply affect both insulin secretion and metabolism as well as its peripheral action. In particular FFAs are able to affect insulin secretion, to decrease hepatic insulin clearance, to stimulate gluconeogenesis in the liver and to reduce peripheral glucose utilization. An enhanced Substrates and insulin R Vettor et al S23 blood lactate concentration may increase insulin secretion as well as hepatic insulin clearance. Moreover, it decreases whole body glucose disposal without affecting hepatic glucose production. The reduction in heart and red skeletal muscle of insulin induced glucose utilization during lactate infusion, may justify, at least in part, the blunted overall glucose disposal.
Our data con®rm that in insulin resistance states, such as obesity and non-insulin dependent diabetes mellitus, a clear disturbance of lactate metabolism exists. 13 They are in keeping with the hypothesis that lactate might be important in the development of carbohydrate intolerance and insulin resistance. Moreover, lactate and FFA overproduction from the enlarged fat mass and, in particular, from visceral fat depots of obese patients may secondarily interfere with peripheral glucose metabolism leading to insulin resistance and accelerating the progression of obesity towards diabetes.
